医学
肿瘤科
联合疗法
抗体-药物偶联物
膀胱癌
化疗
药品
内科学
临床试验
靶向治疗
免疫疗法
抗体疗法
癌症
抗体
免疫学
单克隆抗体
药理学
作者
Xiangyun You,Chunming Zhu,Puguang Yu,Xia Wang,Yibing Wang,Jiahe Wang,Junfeng Yu,Kefeng Wang
标识
DOI:10.1016/j.biopha.2024.116152
摘要
Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system. Although there are various treatment modalities, including surgery, chemotherapy, and immune checkpoint inhibitor (ICI) therapy, some patients experience disease recurrence and metastasis with poor prognosis and dismal long-term survival. Antibody–drug conjugates (ADCs), which combine the targeting ability of antibody drugs with the cytotoxicity of chemotherapeutic drugs, have recently emerged as a prominent research focus in the development of individualized precision cancer therapy. Although ADCs have improved the overall response rate in patients with UC, their effectiveness remains limited. Currently, ADC-based combination therapies, particularly ADC combined with ICIs, have demonstrated promising efficacy. This combination approach has advanced the treatment of UC, exhibiting the potential to become the standard first-line therapy for advanced UC in the future. This article reviewed clinical trials involving ADC-based combination therapy for UC and discussed the possible challenges and future perspectives to provide guidance for the clinical treatment of UC.
科研通智能强力驱动
Strongly Powered by AbleSci AI